An attribute of temozolomide treatment in glioma cells is over-activated antioxidant systems, with high GSH and GR content; furthermore, the suppression of GSH sensitizes glioma cells to temozolomide (Zhu et al., 2018). This evidence concerns the gene GSR and glioma.